George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Has anyone started to notice that since no one listens to his charting anymore (as he has been found to be soo wrong on multiple occasions) wynbore is now shifting to the fundamentals, where he clearly struggles with understanding?
"No one on this board knows how good AVA6000 is compared to standard Doxorubicin"
Erm....... No side effects will providing therapeutic benefit. I think its just the FUDSTERS that struggle understanding that
Milestone payments are fixed depending on milestone achieved and were agreed when avacta was still in pre clinical stage, and therefore couldn't command big numbers.
These thoughts are very silly an uninformed... Please folk, when it comes to biotech, this account is clueless. Shockingly clueless. Like WTF clueless.